Drug repositioning for Alzheimer's disease

Anne Corbett, James Pickett, Alistair Burns, Jonathan Corcoran, Stephen B Dunnett, Paul Edison, Jim J Hagan, Clive Holmes, Emma Jones, Cornelius Katona, Ian Kearns, Patrick Kehoe, Amrit Mudher, Anthony Passmore, Nicola Shepherd, Frank Walsh, Clive Ballard, Peter Passmore

Research output: Contribution to journalArticlepeer-review

180 Citations (Scopus)


Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.
Original languageEnglish
Pages (from-to)833-46
Number of pages14
JournalNature reviews. Drug discovery
Issue number11
Publication statusPublished - Nov 2012

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Drug repositioning for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this